TG Therapeutics (TGTX)
(Real Time Quote from BATS)
$27.73 USD
-0.67 (-2.36%)
Updated Aug 6, 2025 11:32 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TGTX 27.73 -0.67(-2.36%)
Will TGTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TGTX
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
Company News for Aug 5, 2025
TGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Other News for TGTX
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
TGTX Stock Drops Over 14% Following Latest Market Movements
Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz
Q2 2025 TG Therapeutics Inc Earnings Call Transcript